Video: Wuxi’s Mission Critical – Fostering Innovation by Servicing Biopharma

Wuxi

It might act like a biopharmaceutical firm, but Wuxi Apptec’s Richard M. Soll, senior VP, International Discovery Service Unit, told BioWorld it’s still a CRO. He also discussed Wuxi’s role in helping to obtain the first U.S. FDA approval of a biologic product made by a Chinese company. (more…)

Share on LinkedInTweet about this on TwitterShare on Google+Share on FacebookShare on RedditDigg thisEmail this to someone

Japan and China: Challenging Strategies in the Global Device Market

medical devices

Medical devices play an increasingly vital role in health care delivery. In Asia, 2 major players in the medical device industry—Japan and China—share strategic importance to the global market.

  • Japan: world’s second largest market after the US, estimated at $30 billion USD*
  • China: world’s fourth largest market, soon the third, estimated at $14 billion USD*, and with high growth rate, the potential is huge

(more…)

Share on LinkedInTweet about this on TwitterShare on Google+Share on FacebookShare on RedditDigg thisEmail this to someone

New Drugs for Obesity and Diabetes

Contrave

In the last few weeks, a number of new agents have taken strides toward launch onto the diabetes and obesity markets, which both represent large and commercially lucrative market sectors. Diabetes affects approximately 350 million people worldwide, including a staggering 9.3% of the US population. It is the leading cause of blindness, amputation and kidney failure, and is predicted by the WHO to be the seventh leading cause of death by 2030. (more…)

Share on LinkedInTweet about this on TwitterShare on Google+Share on FacebookShare on RedditDigg thisEmail this to someone

A Dendritic Cell ‘Vaccine’ is a First for ‘Promising Innovative Medicine’ (PIM) Status in the U.K.

Promising Innovative Medicine

‘Promising Innovative Medicine’ (PIM) status has been given in the U.K. for the first time, for a vaccine to treat cerebral glioblastoma multiforme (GBM). Northwest Biotherapeutics (NWBT), Bethesda, Maryland, U.S.A. developed the DCVax®-L vaccine which may now, under PIM status, be used as an adjunct to treat these aggressive brain tumours in patients in the U.K. (more…)

Share on LinkedInTweet about this on TwitterShare on Google+Share on FacebookShare on RedditDigg thisEmail this to someone

FDA Suggests Reintroduction of Bovine-Derviced Heparin

Heparin

During an advisory committee meeting with its Science Board in early June, the FDA suggested a reintroduction into the US market of bovine-derived heparin. Despite theoretical risks associated with bovine-derived products, heparin is a vital product for clinical use, FDA representatives argued, and single animal/country specific sourcing is risky. (more…)

Share on LinkedInTweet about this on TwitterShare on Google+Share on FacebookShare on RedditDigg thisEmail this to someone

Navigating Clinical Trials in Russia: the Challenges, Solutions and Benefits

Clinical Trials in Russia

Slated to rise from 11th to 8th place in the global pharmaceutical rankings, Russia is steadily proving to be a lucrative market for investors. With increased healthcare expenditure and governmental support of innovation through the implementation of Strategy 2020, policymaking and industry reform are shaping Russia’s drug development landscape. Efforts to localize pharmaceutical manufacturing and increase domestic R&D have been successful. Most of large pharma has set up camp in the country and remains present despite a drop in clinical trials in 2013. (more…)

Share on LinkedInTweet about this on TwitterShare on Google+Share on FacebookShare on RedditDigg thisEmail this to someone

How Changes to Strategic Portfolio Development are Affecting Generics & API Manufacturers

API Manufacturers

Medical treatments are becoming increasingly specialized, personalized, and targeted to specific therapies. The shift in drug portfolios has impacted not only the innovation landscape, but also the generic drug landscape and the active ingredient landscape. Understanding how these shifts will impact your business strategies, partnerships, and potential competition is critical for your company’s long term growth and success. (more…)

Share on LinkedInTweet about this on TwitterShare on Google+Share on FacebookShare on RedditDigg thisEmail this to someone

Creating Strategic Value In The Changing Generics Market: CPhI Worldwide 6th Annual Pre-Connect Congress

API Sourcing

“The patent cliff is changing the patterns of generic competition.” – Kate Kuhrt, Senior Director, Generics, Thomson Reuters

 

The day before the official start of the CPhI Worldwide tradeshow in Paris, several hundred attendees gathered once again for a day of presentations, discussions, and debate on topics impacting the pharmaceutical industry. Participants in the program could choose between commercial and technical tracks. (more…)

Share on LinkedInTweet about this on TwitterShare on Google+Share on FacebookShare on RedditDigg thisEmail this to someone

Anticancer Protein Kinase Inhibitors: Strengths, Weaknesses, Opportunities and Threats

Kinase

Signal transduction in cancer cells is a sophisticated process that involves receptor tyrosine kinases to trigger cellular signaling pathways in order to promote growth, pro-apoptotic signaling and angiogenesis, and ultimately cancer development. Molecularly targeted anticancer therapies using either small molecules or antibodies to these tyrosine kinases have been successfully introduced to treat various cancers, and the future of anticancer therapy may largely lay with agents such as these, particularly as more is learned about cancer cell biology. Thomson Reuters analysts have assessed the strengths, weaknesses, opportunities and threats for the therapeutic agents in this area; selected highlights are presented. (more…)

Share on LinkedInTweet about this on TwitterShare on Google+Share on FacebookShare on RedditDigg thisEmail this to someone

Get More out of your Data by Extending Collaboration with Partners

big data

Most Big Data initiatives are inherently selfish. The vision is that all you need to do is build your data “lake” and then enlightenment will simply emerge from patterns in your own data. This article will address what Big Data means in a collaborative world. (more…)

Share on LinkedInTweet about this on TwitterShare on Google+Share on FacebookShare on RedditDigg thisEmail this to someone